A Phase 3 interventional study of Test toothpaste and Control toothpaste in Hypersensitivity, sponsored by Colgate Palmolive. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-22.
Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hypersensitivity with a site in China — 9 open to participants now, 9 under way, 1 of them phase 3. Hypersensitivity · China.
Among the 35 studies in Hypersensitivity with a site in China, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 26th registered.
1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →9 of the 35 studies in Hypersensitivity with a site in China are open now. Recruiting first, the newest first:
Qifeng Zhang · Sites in China, United States
Bo Wang,MD · Sites in China
Ages 18+
Min-Tze LIONG · Sites in China, Malaysia
Ages 0 mo–36 mo · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 14–90
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 25–70 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 73 across 693 interventional studies indexed under Hypersensitivity.
Median enrollment 200 across the 20 interventional studies, 180 across the 15 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 35 have an industry lead sponsor. The 10 most frequent:
Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.
Colgate Palmolive has 5 studies filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypersensitivity with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07945665Phase 3Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Hypersensitivity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the clinical efficacy of a Dual Zinc Toothpast containing 5% small particle size silica (AC43) as compared to Colgate MaxFresh Tea Toothpaste on dentin hypersensitivity reduction after brushing two times daily (morning and evening) for a period of 8 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be instructed to brush their teeth with their assigned test dentifrice and toothbrush twice daily
Drug: Test toothpaste
Subjects will be instructed to brush their teeth with their assigned test dentifrice and toothbrush twice daily
Drug: Control toothpaste
A commercially available fluoride toothpaste
A commercially available fluoride toothpaste
tactile sensitivity
tactile stimulation is measured by the Yeaple Electronic Force Sensing Probe
Time frame: baseline and 8 week measurement
air blast sensitivity
air blast sensitivity is delivered by a standard dental unit syringe at a measured temperature of 19-21°C (70°F \[± 3°F\]) \[sensitivity will be defined by a score of 2 or 3 on the Schiff Cold Air sensitivity scale Air Sensitivity Scale
Time frame: baseline and 8 week measurement
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Dec 2024, 2 months.
Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 2 months is below that.
Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.